GlaxoSmithKline P.L.C. signed a deal yesterday to develop drugs to treat rheumatoid arthritis and other inflammatory diseases. The agreement to work with Chroma Therapeutics Ltd. of Oxford, England, to develop new products represents Glaxo's latest effort to overhaul its research and development programs so it more closely resembles a small, nimble biotechnology company rather than a lumbering pharmaceutical giant.
Copyright PHILY - Philly.com
